GH RESEARCH PLC
GH Research plc (GHRS) is a clinical-stage biotechnology company developing novel therapeutics inspired by classic psychedelics for neuropsychiatric disorders, including major depressive disorder and suicidal ideation. The company’s pipeline focuses on proprietary formulations and dosing regimens intended to deliver therapeutic benefits while managing safety and tolerability; its assets are in clinical development. With a market capitalisation of approximately $791.5m, GH Research attracts investor interest because of its targeted approach and the wider resurgence of research into psychedelic-derived medicines. However, it remains an early-stage biopharma: outcomes depend on clinical trial results, regulatory review and commercial adoption. Investors should be aware of typical sector risks — binary trial catalysts, potential dilution from fund-raising, and variable timelines. This summary is for educational purposes only and not personal financial advice; suitability depends on an investor’s goals, risk tolerance and time horizon.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GH Research stock, expecting its price to rise significantly in the future.
Financial Health
GH Research is doing well with strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GHRS
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Focus on psychedelic-inspired candidates means clinical trial results can be significant catalysts, though outcomes are uncertain and timelines can shift.
Rising research interest
Growing scientific and investor attention on psychedelic-based treatments could support long-term interest, but regulatory and commercial adoption remain to be proven.
Key near-term catalysts
Upcoming trial readouts and regulatory interactions may move the share price; investors should note the binary nature of such events and associated volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
